PROCEPT BioRobotics (PRCT) stock
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on PRCT
| Since its 2024 high | Down 81% |
| Latest filing | 8-K, Oct 2 |
PRCT in the news
ReportReports Wednesday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -2.1% on average. Past reports ›
PRCT catalysts
After its last 4 reports it closed -2.1% on average, higher 2 of 4 times.
Why PRCT scores -5
Poorfor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- −3Long-term trend below a falling 200-day average, down over one year, down over two years
- Profit subtracts
- Growth adds
- Volatility subtracts
- Cash flow subtracts
- Insider trades subtracts
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
PRCT has 3 of 14 chart checks firing
PRCT RSI today: 52.3, above its 50-day, below its 200-day
- RSI 1452.3
- MACD (12, 26, 9)Above signal
- 50-day average$19.36
- 200-day average$23.27
- 50/200 crossDeath cross
- ADX 1421.0
- Support$19.35
- Resistance$19.87
- 52-week high$38.11
- 52-week low$16.66
- Chart patternNone
- Bollinger Bands (20, 2)Inside
- Volume1.2x
The deep dive on PRCT
- What it does and how it makes moneySEC filing · Feb 26, 2026
- Where it stands
- What changed in its filingsSEC filing · Feb 26, 2026, against the one of Feb 27, 2025
- Who holds and trades itForm 4, filed Aug 10, 2026
How PRCT ranks in Medical Devices
PRCT is #81 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 81 |
When does PRCT report earnings, and what happens after?
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What PRCT reported on Aug 4, 2026
The quarter
The figures are not read from the release yet.
“The increase was driven by increased U.S. handpiece and system revenue and international revenue.”
Where the sales came from
PRCT's results filing gives no sales by line in a table we read.
The outlook
| Measure | Figure |
|---|---|
| Revenue | $390M to $410M |
In the company's words
“Gross margin increase in the second quarter was primarily driven by increased U.S. system and consumable pricing; and a $2.9 million tariff refund.”
From its results filing (SEC filing · Aug 4)
The numbers
- $1.2B
- today
- $337M
- up 22.7% on the year
- -$84.9M
- last 12 months
Sales grew 60% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 7.8% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 4, 2026 | -4.5% | +5.8% | +25.2% |
| Apr 29, 2026 | +10.9% | +10.7% | +14.2% |
| Feb 25, 2026 | -29.6% | -15.1% | -4.6% |
PRCT sales and profit by year
Sales grew every year from 2020 to 2025, to $308M. It lost money in each of the six years.
Insiders trading PRCT
PRCT insider trades
One insider bought $498K across 1 filing, and 3 insiders sold $50K across 6 filings, in the last 6 months. The newest:
PRCT's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold PRCT?
In ETFs: PRCT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
What PROCEPT BioRobotics says it competes with
“While we believe Aquablation therapy delivered through our robotic systems provides us with a competitive advantage against other competing BPH treatment modalities, our currently marketed products are, and any future products we commercialize will be, subject to intense competition.”
PRCT's score card
Pro members see every line of every stock's score.
- What would turn PRCT's score around: 8 things
- 3 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is PRCT a good stock to buy? What its Quality Score says
PRCT scores -5 today, which Breakaway calls Poor. It is #81 of 85 in Medical Devices by Quality Score, with 3 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is PRCT's Quality Score?
PRCT scores -5 today, which Breakaway calls Poor (below zero). That is #81 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PRCT's -5.
Are insiders buying PRCT?
One insider bought $498K across 1 filing, and 3 insiders sold $50K across 6 filings, in the last 6 months. The newest is Barry L. Templin, EVP, Chief Technology Officer, who sold $8K on Sep 9. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.